Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.

We conducted a systematic review to estimate efficacy and safety of ixabepilone plus capecitabine compared with capecitabine alone for patients of anthracycline- and/or taxane-resistant metastatic breast cancer.